Gilead Sciences (GILD): Why Splitting GILD Is A Bad Idea - Piper Jaffray
- Wall Street falls as post-election winners lag
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- United Airlines (UAL) Tops Q4 EPS by 5c
- Big 5 Sporting Goods (BGFV) Q4 Comps Rise 3.1%; Guides Q4 Above the Street
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Piper Jaffray analyst, Joshua Schimmer, reiterated his Overweight rating on shares of Gilead Sciences (NASDAQ: GILD) along with his price target of $108 while shedding light on the myth that breaking up GILD is a good idea.
The analyst believes that breaking up GILD into its HIV and HCV franchises could reduce the hyper-focus on HCV which is distracting the company from a materially undervalued and robust HIV business (that includes bictegravir/Descovy). The analyst thinks splitting up the company is a poor idea and the probability of this occurring is negligible.
Separating HIV and HCV will require replication of sales forces, commercial infrastructure, administrative efforts and virology R&D. It would also have to address tax considerations and ex-US cash.
Shares of Gilead Sciences closed at $80.59 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: JPMorgan Downgrades OneMain (OMF) to Neutral
- Mizuho Securities Raises Price Target on Noble Energy (NBL) to $48; Reiterates Buy
- FBR Capital Remains Sidelined on Comerica (CMA) Following 4Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesPiper Jaffray, Joshua Schimmer
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!